{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T03:33:16Z","timestamp":1793763196602,"version":"4.6.1"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.ejpb.2026.115262","type":"journal-article","created":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T14:38:08Z","timestamp":1791729488000},"page":"115262","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Structure\u2013interaction\u2013performance relationships in quercetin-based co-amorphous systems: insights from molecular simulations and experimental characterization"],"prefix":"10.1016","volume":"229","author":[{"given":"Iqra","family":"Aslam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0988-7651","authenticated-orcid":false,"given":"Abinash","family":"Nayak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohd Fakharul","family":"Zaman Raja Yahya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2437-0471","authenticated-orcid":false,"given":"Isra","family":"Khatib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4308-027X","authenticated-orcid":false,"given":"Niall J.","family":"O\u2019Reilly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5219-3658","authenticated-orcid":false,"given":"Nasser","family":"Alhajj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2026.115262_b0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2022.106324","article-title":"CADD, AI and ML in drug discovery: a comprehensive review","volume":"181","author":"Vemula","year":"2023","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2026.115262_b0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejpb.2024.114513","article-title":"Pharmaceutical approaches for enhancing solubility and oral bioavailability of poorly soluble drugs","volume":"204","author":"Nyamba","year":"2024","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2026.115262_b0015","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1023\/A:1007516718048","article-title":"What is the true solubility advantage for amorphous pharmaceuticals?","volume":"17","author":"Hancock","year":"2000","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2026.115262_b0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.119925","article-title":"Physical stability of amorphous pharmaceutical solids: nucleation, crystal growth, phase separation and effects of the polymers","volume":"590","author":"Shi","year":"2020","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2026.115262_b0025","article-title":"Co-amorphous systems in drug delivery: Mechanistic insights, stability challenges, and future perspectives","volume":"120","author":"Srividya","year":"2026","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.ejpb.2026.115262_b0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2017.08.123","article-title":"Supersaturating drug delivery systems: the potential of co-amorphous drug formulations","volume":"532","author":"Laitinen","year":"2017","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2026.115262_b0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejpb.2025.114972","article-title":"Sulfasalazine\u2013quercetin co-amorphous systems: sustained release behaviors and enhanced pharmacokinetics","volume":"220","author":"Deng","year":"2026","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2026.115262_b0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2023.106654","article-title":"Development and characterization of a spray-dried inhalable ternary combination for the treatment of P. aeruginosa biofilm infection in cystic fibrosis","volume":"192","author":"Alhajj","year":"2024","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2026.115262_b0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.121657","article-title":"Development and characterization of a spray-dried inhalable ciprofloxacin-quercetin co-amorphous system","volume":"618","author":"Alhajj","year":"2022","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2026.115262_b0050","doi-asserted-by":"crossref","unstructured":"N.S. K. S., S.J. Dengale, S. Mutalik, K. Bhat, Raloxifene HCl \u2013 quercetin co-amorphous system: preparation, characterization, and investigation of its behavior in phosphate buffer, Drug Dev. Ind. Pharm. 48 (2022) 227\u2013238. https:\/\/doi.org\/10.1080\/03639045.2022.2104308.","DOI":"10.1080\/03639045.2022.2104308"},{"key":"10.1016\/j.ejpb.2026.115262_b0055","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1093\/jaoacint\/qsab024","article-title":"Dronedarone HCl \u2013 Quercetin Co-Amorphous System: Characterization and RP - HPLC Method Development for Simultaneous Estimation","volume":"104","author":"Navya Sree","year":"2021","journal-title":"J. AOAC Int."},{"key":"10.1016\/j.ejpb.2026.115262_b0060","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3390\/pharmaceutics13020171","article-title":"Co-amorphous formulations of furosemide with arginine and p-glycoprotein inhibitor drugs","volume":"13","author":"Ruponen","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2026.115262_b0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2019.118653","article-title":"The effect of co-amorphization of glibenclamide on its dissolution properties and permeability through an MDCKII-MDR1 cell layer","volume":"570","author":"Sormunen","year":"2019","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2026.115262_b0070","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ejpb.2014.12.025","article-title":"Fabrication, solid state characterization and bioavailability assessment of stable binary amorphous phases of Ritonavir with Quercetin","volume":"89","author":"Dengale","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2026.115262_b0075","article-title":"Pellets containing quercetin amino acid co-amorphous mixture for the treatment of pain: Formulation, optimization, in-vitro and in-vivo study","volume":"62","author":"Hatwar","year":"2021","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.ejpb.2026.115262_b0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2020.105582","article-title":"Comparison of co-former performance in co-amorphous formulations: Single amino acids, amino acid physical mixtures, amino acid salts and dipeptides as co-formers","volume":"156","author":"Wu","year":"2021","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2026.115262_b0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2026.126744","article-title":"Interplay of solute crystallization and drying potential in controlling spray dried particle morphology","volume":"694","author":"Alhajj","year":"2026","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2026.115262_b0090","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.powtec.2021.02.031","article-title":"Designing enhanced spray dried particles for inhalation: a review of the impact of excipients and processing parameters on particle properties","volume":"384","author":"Alhajj","year":"2021","journal-title":"Powder Technol."},{"key":"10.1016\/j.ejpb.2026.115262_b0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.cej.2025.165093","article-title":"An efficient design strategy for flavonoid co-amorphous systems and enhanced their antioxidant and antibacterial activities for application potential in food preservation and functional products","volume":"519","author":"Han","year":"2025","journal-title":"Chem. Eng. J."},{"key":"10.1016\/j.ejpb.2026.115262_b0100","doi-asserted-by":"crossref","first-page":"3045","DOI":"10.1021\/acs.molpharmaceut.4c01536","article-title":"Design of coamorphous systems for flavonoid components coformed with meglumine by integrating theory-model-experiment techniques","volume":"22","author":"Han","year":"2025","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2026.115262_b0105","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1080\/08927022.2025.2567932","article-title":"Molecular simulation of polymer blend miscibility: a predictive thermodynamic framework anchored in Flory-Huggins interaction metrics","volume":"51","author":"Haider Gilani","year":"2025","journal-title":"Mol. Simul."},{"key":"10.1016\/j.ejpb.2026.115262_b0110","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.1021\/acs.jpclett.8b01123","article-title":"Molecular electrostatic potential: a new tool to predict the lithiation process of organic battery materials","volume":"9","author":"Liu","year":"2018","journal-title":"J. Phys. Chem. Lett."},{"key":"10.1016\/j.ejpb.2026.115262_b0115","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.jconrel.2023.01.019","article-title":"Mechanistic insights into the crystallization of coamorphous drug systems","volume":"354","author":"Heng","year":"2023","journal-title":"J. Controlled Release"},{"key":"10.1016\/j.ejpb.2026.115262_b0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.ces.2023.118618","article-title":"Prediction of co-amorphous formation using non-bonded interaction energy: Molecular dynamic simulation and experimental validation","volume":"272","author":"Deng","year":"2023","journal-title":"Chem. Eng. Sci."},{"key":"10.1016\/j.ejpb.2026.115262_b0125","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.mattod.2025.05.017","article-title":"Negative mixing enthalpy route guides strong and ductile soft magnetic high-entropy alloys with high saturation magnetization","volume":"88","author":"Zhao","year":"2025","journal-title":"Mater. Today"},{"key":"10.1016\/j.ejpb.2026.115262_b0130","doi-asserted-by":"crossref","first-page":"850","DOI":"10.3390\/pharmaceutics17070850","article-title":"Cutting-edge approaches in the co-amorphization process","volume":"17","author":"Mahmoud","year":"2025","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2026.115262_b0135","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1021\/acs.molpharmaceut.9b00275","article-title":"Assessing physical stability risk using the amorphous classification system (ACS) based on simple thermal analysis","volume":"16","author":"Zhou","year":"2019","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2026.115262_b0140","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1021\/acs.molpharmaceut.1c00519","article-title":"What are the important factors that influence API crystallization in miscible amorphous API\u2013excipient mixtures during long-term storage in the glassy state?","volume":"19","author":"Newman","year":"2022","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2026.115262_b0145","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1021\/acs.chemrev.1c00237","article-title":"Structural analysis of molecular materials using the pair distribution function","volume":"122","author":"Terban","year":"2022","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ejpb.2026.115262_b0150","series-title":"High-resolution NMR techniques in organic chemistry","author":"Claridge","year":"2016"},{"key":"10.1016\/j.ejpb.2026.115262_b0155","unstructured":"M. Heneczkowski, M. Kopacz, D. Nowak, A. Ku\u017aniar, Infrared spectrum analysis of some flavonoids, Acta Pol. Pharm. - Drug Res. 58 (2001) 415\u2013420. https:\/\/www.scopus.com\/inward\/record.uri?eid=2-s2.0-0035694832&partnerID=40&md5=83981e86185a6f1c3bd969d60e8893af."},{"key":"10.1016\/j.ejpb.2026.115262_b0160","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.vibspec.2016.11.007","article-title":"Molecular structure and vibrational spectra of quercetin and quercetin-5\u2019-sulfonic acid","volume":"88","author":"Hanuza","year":"2017","journal-title":"Vib. Spectrosc"},{"key":"10.1016\/j.ejpb.2026.115262_b0165","first-page":"631","article-title":"ATR-FTIR spectroscopy: its advantage and limitations","volume":"49","author":"Grdadolnik","year":"2002","journal-title":"Acta Chim. Slov."},{"key":"10.1016\/j.ejpb.2026.115262_b0170","doi-asserted-by":"crossref","unstructured":"H. Kaur, B. Rana, D. Tomar, S. Kaur, K.C. Jena, Fundamentals of ATR-FTIR Spectroscopy and Its Role for Probing In-Situ Molecular-Level Interactions, in: D.K. Singh, M. Pradhan, A. Materny (Eds.), Mod. Tech. Spectrosc. Basics Instrum. Appl., Springer Singapore, Singapore, 2021: pp. 3\u201337. https:\/\/doi.org\/10.1007\/978-981-33-6084-6_1.","DOI":"10.1007\/978-981-33-6084-6_1"},{"key":"10.1016\/j.ejpb.2026.115262_b0175","series-title":"Statistics and chemometrics for analytical chemistry","author":"Miller","year":"2018"},{"key":"10.1016\/j.ejpb.2026.115262_b0180","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1021\/js9601896","article-title":"Characteristics and significance of the amorphous state in pharmaceutical systems","volume":"86","author":"Hancock","year":"1997","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2026.115262_b0185","first-page":"27","article-title":"Amorphous pharmaceutical solids: preparation, characterization and stabilization","volume":"48","author":"Yu","year":"2001","journal-title":"Charact. Solid State"},{"key":"10.1016\/j.ejpb.2026.115262_b0190","doi-asserted-by":"crossref","first-page":"6630","DOI":"10.3390\/molecules27196630","article-title":"On the thermodynamic thermal properties of quercetin and similar pharmaceuticals","volume":"27","author":"Tsioptsias","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.ejpb.2026.115262_b0195","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1007\/s10765-021-02911-z","article-title":"Heat capacities of l-Arginine, l-Aspartic Acid, l-Glutamic Acid, l-Glutamine, and l-Asparagine","volume":"42","author":"Pokorn\u00fd","year":"2021","journal-title":"Int. J. Thermophys."},{"key":"10.1016\/j.ejpb.2026.115262_b0240","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1021\/acs.molpharmaceut.0c00042","article-title":"Determination of the optimal molar ratio in amino acid-based coamorphous systems","volume":"17","author":"Liu","year":"2020","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2026.115262_b0200","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.ijpharm.2010.05.033","article-title":"Is a distinctive single Tg a reliable indicator for the homogeneity of amorphous solid dispersion?","volume":"395","author":"Qian","year":"2010","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2026.115262_b0205","doi-asserted-by":"crossref","first-page":"5045","DOI":"10.1021\/acs.jpca.6c01567","article-title":"From atomic interactions to molecular miscibility and philicity: deciphering enthalpic driving forces","volume":"130","author":"Upterworth","year":"2026","journal-title":"J. Phys. Chem. A"},{"key":"10.1016\/j.ejpb.2026.115262_b0210","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.addr.2017.03.002","article-title":"Pharmaceutical solvates, hydrates and amorphous forms: a special emphasis on cocrystals","volume":"117","author":"Healy","year":"2017","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2026.115262_b0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.molliq.2022.120756","article-title":"Enhancement of water solubilization of quercetin by meglumine and application of the solubilization concept to a similar system","volume":"368","author":"Fusina","year":"2022","journal-title":"J. Mol. Liq."},{"key":"10.1016\/j.ejpb.2026.115262_b0220","doi-asserted-by":"crossref","unstructured":"V. Sai Krishna Anand, S.D. Sakhare, K.S. Navya Sree, A.R. Nair, K. Raghava Varma, K. Gourishetti, S.J. Dengale, The relevance of co-amorphous formulations to develop supersaturated dosage forms: In-vitro, and ex-vivo investigation of Ritonavir-Lopinavir co-amorphous materials, Eur. J. Pharm. Sci. 123 (2018) 124\u2013134. https:\/\/doi.org\/10.1016\/j.ejps.2018.07.046.","DOI":"10.1016\/j.ejps.2018.07.046"},{"key":"10.1016\/j.ejpb.2026.115262_b0225","doi-asserted-by":"crossref","first-page":"4071","DOI":"10.1021\/acs.molpharmaceut.3c00226","article-title":"Designing a novel coamorphous salt formulation of telmisartan with amlodipine to enhance permeability and oral absorption","volume":"20","author":"Hatanaka","year":"2023","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2026.115262_b0230","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s44446-026-00110-1","article-title":"Co-amorphization for solubility and dissolution rate improvement: the case of low-crystallization-tendency drugs","volume":"34","author":"Budiman","year":"2026","journal-title":"Saudi Pharm. J."},{"key":"10.1016\/j.ejpb.2026.115262_b0235","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s12247-019-09381-9","article-title":"Influence of preparation methods on physicochemical and pharmacokinetic properties of co-amorphous formulations: the case of co-amorphous atorvastatin: naringin","volume":"15","author":"Nair","year":"2020","journal-title":"J. Pharm. Innov."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641126002833?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641126002833?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T03:15:48Z","timestamp":1793762148000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641126002833"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":48,"alternative-id":["S0939641126002833"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2026.115262","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Structure\u2013interaction\u2013performance relationships in quercetin-based co-amorphous systems: insights from molecular simulations and experimental characterization","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2026.115262","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115262"}}